TARO PHARMACEUTICAL INDUSTRIES LTD financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2023.

Latest financial report
29 Jun 2023
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Haifa Bay, Israel
SEC filing record 1 source field available
Fiscal year end
31 March

Shareable Research Card

TARO PHARMACEUTICAL INDUSTRIES LTD Financial Facts

TARO PHARMACEUTICAL INDUSTRIES LTD has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2023

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2023
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2023.
  • Most recent SEC facts end date on this page: 31 Mar 2023.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for TARO PHARMACEUTICAL INDUSTRIES LTD

New fact period available

Latest financial period: Q1 2023. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

29 Jun 2023

Page type

Company facts

Latest period

Q1 2023

SEC-backed company facts were refreshed from filings filed on 29 Jun 2023.

Open recent updates hub Open latest 10-Q/10-K hub

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • TARO PHARMACEUTICAL INDUSTRIES LTD financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2023.
  • Headline metric summary will appear when SEC facts are available.

Change

  • No metrics are currently available for comparison on this facts page.
  • Changes will populate automatically as new 10-Q/10-K periods are processed.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

No market comparison No market comparison Low confidence

Fair value per share

$12.43

Market price

n/a

PEG ratio

n/a

Enterprise value

$312.76M

Equity value

$467.26M

DCF fair value scenarios

Bear

$10.32

No market comparison
Growth
1%
Discount
11%
Terminal
2%

Base

$12.43

No market comparison
Growth
4%
Discount
10%
Terminal
2.5%

Bull

$15.76

No market comparison
Growth
7%
Discount
9%
Terminal
3%

Base growth: DCF Growth Assumption.

Key valuation metrics

EV/Revenue

n/a

Market price market EV / SEC revenue

Market enterprise value is unavailable

EV/EBITDA

n/a

Market price market EV / SEC EBITDA

Market enterprise value is unavailable

P/E

n/a

Market price market price / SEC EPS

Market cap is unavailable

P/S

n/a

Market price market cap / SEC revenue

Market cap is unavailable

P/B

n/a

Market price market cap / SEC equity

Market cap is unavailable

PEG

n/a

P/E / DCF Growth Assumption

P/e or positive growth is unavailable

Core assumptions

Projection
5 years
FCF growth
4%
Discount rate
10%
Terminal growth
2.5%

SEC fact inputs

DCF base FCF
$21.48M
Normalized SEC FCF average
Reported FCF
$14.17M
Net income
$25.44M
EBITDA
$49.84M
Cash
$154.5M
Debt
n/a
Equity
$1.73B
Shares
37,584,891

Data confidence notes

  • Dcf base free cash flow: dcf base starts from trailing sec free cash flow
  • Dcf base free cash flow: trailing free cash flow is below recent annual free cash flow, so dcf uses a normalized sec average
  • Dcf base free cash flow: capital expenditures consume more than half of operating cash flow
  • Dcf confidence is low for this sec-only free cash flow estimate
  • Ticker missing for issuer
  • Debt missing: equity value treats debt as 0
  • Peg uses dcf growth assumption because historical sec growth is not positive
  • Dcf uses fallback growth assumption because historical free cash flow growth is not positive

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

n/a

Insufficient Data Confidence low

Financial Health

Share Metrics

Metric Latest value YoY change
Common Stock, Shares, Outstanding 37,584,631 0%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $3,649,000 +166%
Accrued Liabilities, Current $23,953,000 -4.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $174,996,000 -3.6%
Additional Paid in Capital $262,445,000 0%
Assets $2,135,513,000 -1.9%
Assets, Current $1,336,428,000 -0.11%
Cash and Cash Equivalents, at Carrying Value $154,495,000 -38%
Common Stock, Par or Stated Value Per Share 0 0%
Common Stock, Shares Authorized 200,000,000 0%
Common Stock, Shares, Issued 45,116,262 0%
Contract with Customer, Liability, Current $903,000 -84%
Deferred Income Tax Assets, Net $103,672,000 -17%
Deferred Tax Assets, Gross $131,256,000 -15%
Deferred Tax Assets, Net of Valuation Allowance $109,023,000 -17%
Deferred Tax Assets, Operating Loss Carryforwards $18,477,000 -51%
Deferred Tax Assets, Valuation Allowance $22,233,000 +0.26%
Employee-related Liabilities, Current $23,055,000 -3.4%
Goodwill $17,231,000 +46%
Inventory, Net $226,669,000 +7.7%
Lessee, Operating Lease, Liability, to be Paid $4,049,000 -34%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,768,000 -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $874,000 -32%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,407,000 -11%
Liabilities $404,654,000 -13%
Liabilities and Equity $2,135,513,000 -1.9%
Liabilities, Current $385,548,000 -11%
Marketable Securities, Current $575,814,000 +10%
Operating Lease, Liability, Current $1,950,000 -12%
Operating Lease, Right-of-Use Asset $3,872,000 -29%
Other Assets, Noncurrent $83,147,000 +24%
Other Liabilities, Noncurrent $19,106,000 -42%
Property, Plant and Equipment, Gross $521,717,000 +2.2%
Property, Plant and Equipment, Net $190,139,000 -4.8%
Retained Earnings (Accumulated Deficit) $2,414,136,000 +1.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1,730,859,000 +1.1%
Unrecognized Tax Benefits $37,493,000 +8.4%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .